Qubigen builds Frontier AI Infrastructure and air-gapped physics runtimes for autonomous drug discovery. Our platform trains directly on sensitive, un-poolable project data, including dark reaction data and historical failures, without centralizing raw IP or leaving the client environment. The Scientific Execution Layer: • Generative Tensor Engines: Automated design of tailored, synthetically feasible scaffolds. • Quantum Chemistry/Physics-Backed Runtimes: GPU-accelerated quantum chemistry (QM) and binding stability validation before synthesis. • Zero-Egress Federated Architecture: Patented federated learning (187x more cost-effective than traditional FL) keeping project walls 100% intact. We deliver measurable performance gains on real commercial datasets (including a 35%+ uplift in BBB permeability prediction and 130% improvement on dark reaction predictive accuracy). Delivered as specialized execution runtimes for enterprise pharma or as an IP-defensible capability for CROs. * *Case studies and benchmark data available under NDA.
| Website | http://www.qubigen.com |
| Employees | 8 (4 on RocketReach) |
| Founded | 2024 |
| Address | Bio21 Institute, 30 Flemington Rd, Parkville, Melbourne, Victoria 3052, AU |
| Industry | Biotechnology Research |
Looking for a particular Qubigen employee's phone or email?
Jonathan Hall is the Founder and CEO of Qubigen.
4 people are employed at Qubigen.
Qubigen is based in Melbourne, Victoria.